Upstream Bio, founded with the mission to conquer inflammation at its source, is a clinical-stage company specializing in the development of monoclonal antibody therapies. The company's primary focus is on severe asthma, targeting the TSLP receptor to inhibit various immune signaling cascades. By addressing this validated target, Upstream Bio aims to alleviate the burden of inflammatory and allergic diseases on patients and their families.
Notable figures affiliated with Upstream Bio include industry veterans with substantial experience in biopharmaceuticals. The company has garnered attention from key investors in the healthcare sector, reflecting confidence in its innovative approach. Among its achievements, Upstream Bio has advanced its lead antibody therapy into clinical trials, marking significant progress in its mission to provide effective treatments for severe asthma and related conditions.
